Endobronchial Valve System Now Approved in US for Treatment of Severe Emphysema

Endobronchial Valve System Now Approved in US for Treatment of Severe Emphysema
The U.S. Food and Drug Administration has approved Olympus' Spiration Valve System (SVS) as a minimally invasive treatment for severe emphysema, a progressive form of chronic obstructive pulmonary disease (COPD). The approval is based on positive results from the EMPROVE clinical trial (NCT01812447), which showed meaningful improvements in lung function and quality of life in emphysema patients treated with SVS. In emphysema, the walls of the alveoli (the small sacs where gas exchanges occur in the lungs) break down, resulting in a loss of the natural recoil of the lungs. With each inhaled breath, air gets trapped in the diseased portions of the lungs, leading to hyperinflation. In hyperinflated lungs, trapped air compresses healthier lung tissue and flattens the diaphragm, making it difficult to breathe. Minimally invasive endobronchial valves are now recommended for the treatment of severe emphysema over more invasive options, such as lung volume reduction surgery.  The risk-benefit assessment of the SVS
Subscribe or log in to read the rest of this content.